Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling

Annals of the Rheumatic Diseases

Volumn 69, Issue 8, 2010, Pages 1533-1538

  Kadri, Abderrahim ^a   Funck Brentano, Thomas ^a   Lin, Hilène ^a   Ea, Hang Korng ^a   Hannouche, Didier ^b   Marty, Caroline ^a   Lioté, Frédéric ^a   Geoffroy, Valérie ^a   Cohen Solal, Martine E ^a  

^a INSERM   (France)

^b Paris university   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; PAMIDRONIC ACID; TRANSCRIPTION FACTOR RUNX2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CARTILAGE; CARTILAGE CELL; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; GENE OVEREXPRESSION; HISTOPATHOLOGY; JOINT INSTABILITY; MALE; MENISCECTOMY; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIBIA; WILD TYPE;

EID: 77955438432     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.124586     Document Type: Article

References (36)

1. Goldring MB, Berenbaum F. The regulation of chondrocyte function by proinfl ammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res 2004;427(Suppl):S37-46.
2. Pelletier JP, Boileau C, Brunet J, et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004;34:527-38.
3. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005;434:644-8.
4. Glasson SS, Askew R, Sheppard B, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004;50:2547-58.
5. Hunter DJ, Felson DT. Osteoarthritis. Bmj 2006;332:639-42.
6. Lajeunesse D, Reboul P. Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. Curr Opin Rheumatol 2003;15:628-33.
7. Brandt KD, Dieppe P, Radin E. Etiopathogenesis of osteoarthritis. Med Clin North Am 2009;93:1-24, xv.
8. Blair-Levy JM, Watts CE, Fiorentino NM, et al. A type I collagen defect leads to rapidly progressive osteoarthritis in a mouse model. Arthritis Rheum 2008;58:1096-106.
9. Javaid MK, Lynch JA, Tolstykh I, et al. Pre-radiographic MRI fi ndings are associated with onset of knee symptoms: the most study. Osteoarthr Cartil 2010;18:323-8.
10. Roemer FW, Neogi T, Nevitt MC, et al. Subchondral bone marrow lesions are highly associated with, and predict subchondral bone attrition longitudinally: the MOST study. Osteoarthritis Cartilage 2010;18:47-53.
11. Roemer FW, Guermazi A, Javaid MK, et al. Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST Study. A longitudinal multicentre study of knee osteoarthritis. Ann Rheum Dis 2009;68:1461-5.
12. Roemer FW, Zhang Y, Niu J, et al. Tibiofemoral joint osteoarthritis: risk factors for MR-depicted fast cartilage loss over a 30-month period in the multicenter osteoarthritis study. Radiology 2009;252:772-80.
13. Ding M, Odgaard A, Hvid I. Changes in the three-dimensional microstructure of human tibial cancellous bone in early osteoarthritis. J Bone Joint Surg Br 2003;85:906-12.
14. Ding M, Danielsen CC, Hvid I. Age-related three-dimensional microarchitectural adaptations of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int 2006;78:113-22.
15. Botter SM, van Osch GJ, Waarsing JH, et al. Quantifi cation of subchondral bone changes in a murine osteoarthritis model using micro-CT. Biorheology 2006;43:379-88.
16. Hayami T, Pickarski M, Wesolowski GA, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004;50:1193-206.
17. Bingham CO 3rd, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507.
18. Kadri A, Ea HK, Bazille C, et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 2008;58:2379-86.
19. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 2004;50:341-4.
20. Sanchez C, Deberg MA, Piccardi N, et al. Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthr Cartil 2005;13:988-97.
21. Shimizu S, Asou Y, Itoh S, et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007;56:3358-65.
22. Geoffroy V, Kneissel M, Fournier B, et al. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 2002;22:6222-33.
23. Kamekura S, Hoshi K, Shimoaka T, et al. Osteoarthritis development in novel experimental mouse models induced by knee joint instability. Osteoarthr Cartil 2005;13:632-41.
24. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr Cartil 2007;15:1061-9.
25. Little CB, Mittaz L, Belluoccio D, et al. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum 2005;52:1461-72.
26. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-7.
27. Merciris D, Marty C, Collet C, et al. Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo. Am J Pathol 2007;170:1676-85.
28. Hayami T, Pickarski M, Zhuo Y, et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006;38:234-43.
29. Bobinac D, Spanjol J, Zoricic S, et al. Changes in articular cartilage and subchondral bone histomorphometry in osteoarthritic knee joints in humans. Bone 2003;32:284-90.
30. Kamekura S, Kawasaki Y, Hoshi K, et al. Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum 2006;54:2462-70.
31. Lavigne P, Benderdour M, Lajeunesse D, et al. Subchondral and trabecular bone metabolism regulation in canine experimental knee osteoarthritis. Osteoarthr Cartil 2005;13:310-17.
32. Varghese S, Canalis E. Alendronate stimulates collagenase 3 expression in osteoblasts by posttranscriptional mechanisms. J Bone Miner Res 2000;15:2345-51.
33. Wang X, Manner PA, Horner A, et al. Regulation of MMP-13 expression by RUNX2 and FGF2 in osteoarthritic cartilage. Osteoarthr Cartil 2004;12:963-73.
34. Wayne GJ, Deng SJ, Amour A, et al. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem 2007;282:20991-8.
35. Schiltz C, Prouillet C, Marty C, et al. Bone loss induced by Runx2 over-expression in mice is blunted by osteoblastic over-expression of TIMP-1. J Cell Physiol 2010;222:219-29.
36. Garnero P, Aronstein WS, Cohen SB, et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthr Cartil 2008;16:660-6.